# A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC

> **NCT00251524** · PHASE2 · COMPLETED · sponsor: **Veeda Oncology** · enrollment: 69 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Bevacizumab, Oxaliplatin, Pemetrexed

## Key facts

- **NCT ID:** NCT00251524
- **Lead sponsor:** Veeda Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2012-05-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00251524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00251524, "A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00251524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*